Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Genetics of Glycogen-Storage Disease Type II (Pompe Disease) Workup

  • Author: Germaine L Defendi, MD, MS, FAAP; Chief Editor: Maria Descartes, MD  more...
 
Updated: Feb 29, 2016
 

Laboratory Studies

The studies listed below are indicated in Pompe disease (glycogen-storage disease type II [GSD II]).

Serum creatine kinase concentration

The serum creatine kinase (CK) concentration is a general reflection of muscle disease (nonspecific, as many disease processes are characterized by elevated CK levels).

The greatest elevation is seen in patients with infantile, childhood, and juvenile GSD II variants. Values may be 10 times the reference range (ie, elevated abnormal values of 2000 IU/L, with a normal range of 60-305 IU/L).

CK values may be normal in adult-onset GSD II.

Serum aspartate aminotransferase (AST)

Serum aspartate aminotransferase (AST) is a general indicator of hepatic involvement (nonspecific, as many disease processes are characterized by elevated AST levels).

Hepatic transaminase levels are highest among GSD II infantile forms.

Urinary oligosaccharides

Elevated urinary glucose tetrasaccharide is sensitive for GSD II but nonspecific, as this elevation is seen in other glycogen-storage diseases.[18]

Enzyme activity of acid alpha-glucosidase

Definitive diagnosis of Pompe disease requires measurement of acid alpha-glucosidase (GAA) activity. Generally, lower GAA enzyme activity indicates an earlier age onset of the disease process. Complete deficiency (GAA activity <1% of normal controls) is associated with classic infantile-onset GSD II. Partial deficiency (GAA activity 2%-40% of normal controls) is associated with the non-classic infantile-onset and the late-onset forms.[3]

Per the Pompe Disease Diagnostic Working Group 2008, confirmation of GAA activity is recommended from two sample types. GAA enzyme activity can be determined on dried blood spots, cultured skin fibroblasts, or muscle tissue.

Reliable diagnosis can be determined from a dried blood spot, such as sample collection used for State Metabolic Newborn Screening Tests. This test approach is rapid and sensitive.

Historically, cultured skin fibroblasts were used to assess for GAA enzyme activity. This sample type is problematic as it takes 4-6 weeks to harvest the cells, causing a delay in diagnosis and potential initiation of treatment.

A muscle biopsy can help establish a diagnosis, as GSD II is a lysosomal storage disease. Glycogen storage may be seen in the lysosomes of muscle cells as vacuoles that stain with periodic acid-Schiff (PAS). Obtaining this sample type is invasive, and adult-onset Pompe disease among patients with partial GAA enzyme activity may not be confirmed, as 20%-30% of samples from these patients may not show these muscle changes.[19, 20]

Molecular analysis of the GAA gene

Molecular analysis of the GAA gene is available. However, the assay may fail to reveal both mutations in an affected individual. Therefore, DNA testing cannot be used in place of GAA enzyme activity to establish the diagnosis. DNA analysis can be helpful in the identification of carriers in a family with an affected member.

Further confirmation of diagnosis is made when two disease-causing GAA alleles are identified.

Ethnicity and phenotype of the patient help to direct focused testing for one of the three common pathogenic GAA gene variants: p.Asp645Glu, p.Arg854Ter, or c.336-13T>G.

If none of the common variants is detected, a complete gene sequence can be performed.[17]

Next

Imaging Studies

Chest radiography

Chest radiography shows cardiomegaly in patients with infantile-onset GSD II. Radiography also allows for pulmonary field evaluation.[21]

Echocardiography

Echocardiography is used to establish the degree of cardiac involvement.

Echocardiography is an important study, especially in patients diagnosed with infantile-onset GSD II.

Echocardiography findings may assist medical providers to distinguish between the infantile and juvenile-onset forms of GSD II.

Echocardiography is used to determine overall cardiac enlargement (hypertrophic cardiomyopathy) and to diagnose isolated LV thickening, biventricular thickening, or outflow obstruction in advanced disease.

Previous
Next

Other Tests

Electrocardiography

Electrocardiography (ECG) is also used to establish the presence of cardiac involvement, as conduction disturbance is shown.

The characteristic finding is shortening of the PR interval.

Enlargement of the QRS complex also may occur.

Electromyography

Electromyography (EMG) reveals a myopathic pattern in all patients with Pompe disease.

Many patients with Pompe disease exhibit pseudomyotonic discharges (ie, myotonic discharges in the absence of clinical myotonia), fibrillation potentials, and positive waves due to anterior horn cell involvement.

Previous
Next

Procedures

Skin biopsy findings reveal acid alpha-glucosidase activity in cultured fibroblasts.

Muscle biopsy can help establish a diagnosis. Glycogen storage is seen in the lysosomes of muscle cells as vacuoles that stain with PAS.

Previous
Next

Histologic Findings

Histopathological examination of muscle is not necessary to establish diagnosis.

Light microscopy

Light microscopy reveals large glycogen-containing vacuoles in nearly all muscle fibers.

These vacuoles can be further characterized histochemically as secondary lysosomes.

Type I and type II muscle fibers are equally affected.

Electron microscopy

Electron microscopy is used to classify subtypes of the vacuoles in which glycogen accumulates.

Previous
 
 
Contributor Information and Disclosures
Author

Germaine L Defendi, MD, MS, FAAP Associate Clinical Professor, Department of Pediatrics, Olive View-UCLA Medical Center

Germaine L Defendi, MD, MS, FAAP is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Lois J Starr, MD, FAAP Assistant Professor of Pediatrics, Clinical Geneticist, Munroe Meyer Institute for Genetics and Rehabilitation, University of Nebraska Medical Center

Lois J Starr, MD, FAAP is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics

Disclosure: Nothing to disclose.

Chief Editor

Maria Descartes, MD Professor, Department of Human Genetics and Department of Pediatrics, University of Alabama at Birmingham School of Medicine

Maria Descartes, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics and Genomics, American Medical Association, American Society of Human Genetics, Society for Inherited Metabolic Disorders, International Skeletal Dysplasia Society, Southeastern Regional Genetics Group

Disclosure: Nothing to disclose.

Additional Contributors

Edward Kaye, MD Vice President of Clinical Research, Genzyme Corporation

Edward Kaye, MD is a member of the following medical societies: American Academy of Neurology, Society for Inherited Metabolic Disorders, American Society of Gene and Cell Therapy, American Society of Human Genetics, Child Neurology Society

Disclosure: Received salary from Genzyme Corporation for management position.

Margaret M McGovern, MD, PhD Professor and Chair of Pediatrics, Stony Brook University School of Medicine

Margaret M McGovern, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Society of Human Genetics

Disclosure: Nothing to disclose.

Acknowledgements

Jennifer Ibrahim, MD Chief, Genetics Division, St Joseph's Children's Hospital

Jennifer Ibrahim, MD is a member of the following medical societies: American Society of Human Genetics

Disclosure: Nothing to disclose.

References
  1. Chien YH, Hwu WL, Lee NC. Pompe disease: early diagnosis and early treatment make a difference. Pediatr Neonatol. 2013 Aug. 54(4):219-27. [Medline].

  2. van der Beek NA, de Vries JM, Hagemans ML, Hop WC, Kroos MA, Wokke JH, et al. Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis. 2012 Nov 12. 7:88. [Medline]. [Full Text].

  3. Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL,et, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. 2001. 3389-3420.

  4. Martiniuk F, Chen A, Mack A, Arvanitopoulos E, Chen Y, Rom WN, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet. 1998 Aug 27. 79 (1):69-72. [Medline].

  5. Lin CY, Hwang B, Hsiao KJ, Jin YR. Pompe's disease in Chinese and prenatal diagnosis by determination of alpha-glucosidase activity. J Inherit Metab Dis. 1987. 10 (1):11-7. [Medline].

  6. Ausems MG, Verbiest J, Hermans MP, et al. Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet. 1999 Sep. 7(6):713-6. [Medline].

  7. Van der Kraan M, Kroos MA, Joosse M, Bijvoet AG, Verbeet MP, Kleijer WJ, et al. Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. Biochem Biophys Res Commun. 1994 Sep 30. 203 (3):1535-41. [Medline].

  8. Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet. 2004 Feb. 12 (2):87-92. [Medline].

  9. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999 Jan 20. 281 (3):249-54. [Medline].

  10. Miyamoto Y, Etoh Y, Joh R, et al. Adult-onset acid maltase deficiency in siblings. Acta Pathol Jpn. 1985 Nov. 35(6):1533-42. [Medline].

  11. Bulkley BH, Hutchins GM. Pompe's disease presenting as hypertrophic myocardiopathy with Wolff-Parkinson-White syndrome. Am Heart J. 1978 Aug. 96(2):246-52. [Medline].

  12. Galehdari H, Emami M, Mohammadian G, Khodadadi A, Azmoon S, Baradaran M. Detection of a novel mutation in the GAA gene in an Iranian child with glycogen storage disease type II. Arch Iran Med. 2013 Feb. 16(2):126-8. [Medline].

  13. Amiñoso C, Vallespin E, Fernández L, Arrabal LF, Desviat LR, Pérez B, et al. Identification of the first deletion-insertion involving the complete structure of GAA gene and part of CCDC40 gene mediated by an Alu element. Gene. 2013 Apr 25. 519(1):169-72. [Medline].

  14. Kroos MA, Pomponio RJ, Hagemans ML, et al. Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype. Neurology. 2007 Jan 9. 68(2):110-5. [Medline].

  15. Montalvo AL, Bembi B, Donnarumma M, Filocamo M, Parenti G, Rossi M, et al. Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat. 2006 Oct. 27 (10):999-1006. [Medline].

  16. van der Beek NA, Soliman OI, van Capelle CI, Geleijnse ML, Vletter WB, Kroos MA, et al. Cardiac evaluation in children and adults with Pompe disease sharing the common c.-32-13T>G genotype rarely reveals abnormalities. J Neurol Sci. 2008 Dec 15. 275(1-2):46-50. [Medline].

  17. Leslie N, Tinkle BT. Glycogen Storage Disease Type II (Pompe Disease). GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1261/. Available at http://www.ncbi.nlm.nih.gov/books/NBK1261/. May 9, 2013; Accessed: January 20, 2016.

  18. Young SP, Piraud M, Goldstein JL, Zhang H, Rehder C, Laforet P, et al. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques. Am J Med Genet C Semin Med Genet. 2012 Feb 15. 160C (1):50-8. [Medline].

  19. Laforêt P, Nicolino M, Eymard PB, Puech JP, Caillaud C, Poenaru L, et al. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology. 2000 Oct 24. 55 (8):1122-8. [Medline].

  20. Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, et al. The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol. 2005 Aug. 252 (8):875-84. [Medline].

  21. van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003 Aug. 112 (2):332-40. [Medline].

  22. Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009 Sep. 66(3):329-35. [Medline].

  23. Nicolino M, Byrne B, Wraith JE, et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med. 2009 Mar. 11(3):210-9. [Medline].

  24. Merk T, Wibmer T, Schumann C, Krüger S. Glycogen storage disease type II (Pompe disease)--influence of enzyme replacement therapy in adults. Eur J Neurol. 2009 Feb. 16(2):274-7. [Medline].

  25. Forsha D, Li JS, Smith PB, van der Ploeg AT, Kishnani P, Pasquali SK. Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy. Genet Med. 2011 Jul. 13(7):625-631. [Medline]. [Full Text].

  26. [Guideline] Cunniff C. Prenatal screening and diagnosis for pediatricians. Pediatrics. 2004 Sep. 114(3):889-94. [Medline].

  27. Ausems MG, Lochman P, van Diggelen OP, et al. A diagnostic protocol for adult-onset glycogen storage disease type II. Neurology. 1999 Mar 10. 52(4):851-3. [Medline].

  28. Clinical Trials. A Study to Evaluate the Effects of Pharmacological Chaperones in Cells From Patients With Pompe Disease. clinicaltrials.gov. Available at http://clinicaltrials.gov/ct/show/NCT00515398?order=2. Accessed: 2007.

  29. Engel AG, Gomez MR, Seybold ME, Lambert EH. The spectrum and diagnosis of acid maltase deficiency. Neurology. 1973 Jan. 23(1):95-106. [Medline].

  30. Engel AG, Hirschhorn R. Acid maltase deficiency. Engel AG, Franzine-Armstrong C, eds. Myology: Basic and Clinical. New York, NY: McGraw-Hill; 1996. 1533-53.

  31. Hirschhorn R. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. Scriver CR, Beaudet AL, Sly W, Valle E, eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 1995. 2443-64.

  32. Isaacs H, Savage N, Badenhorst M, Whistler T. Acid maltase deficiency: a case study and review of the pathophysiological changes and proposed therapeutic measures. J Neurol Neurosurg Psychiatry. 1986 Sep. 49(9):1011-8. [Medline].

  33. Umapathysivam K, Hopwood JJ, Meikle PJ. Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease. Clin Chem. 2001 Aug. 47(8):1378-83. [Medline].

  34. Van der Beek NA, Hagemans ML, Reuser AJ, et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord. 2009 Feb. 19(2):113-7. [Medline].

  35. Pompe Disease Diagnostic Working Group, Winchester B, Bali D, Bodamer OA, Mengel E, Müller-Felber W, et al. Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol Genet Metab. 2008 Mar. 93 (3):275-81. [Medline].

 
Previous
Next
 
Glycogen-storage disease type II (Pompe disease). Photomicrograph of the liver. Note the intensively stained vacuoles in the hepatocytes (periodic acid-Schiff, original magnification X 27).
Glycogen-storage disease type II (Pompe disease). Photomicrograph of the liver. Note the regular reticular net and hepatocytes vacuolization (Gordon-Sweet stain, original magnification X 25).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.